← All trials
NCT05015439
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- May 31, 2023
- Completion date
- Aug 31, 2023
- First posted
- Aug 20, 2021
- Last posted
- Sep 16, 2021
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Johns Hopkins UniversityLead sponsor
- Johns Hopkins UniversityOverall official - principal investigator
- Canopy Growth CorporationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.